PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.32%
Cash & equivalents declining -7.32% while RVPH's grows 142.43%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-7.32%
Below half of RVPH's 142.43%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.49%
Higher Other Current Assets Growth compared to RVPH's zero value, indicating worse performance.
-6.31%
Below half of RVPH's 115.61%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-8.93%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.62%
Higher Other Non-Current Assets Growth compared to RVPH's zero value, indicating worse performance.
-7.75%
Both RVPH and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-6.35%
Below half of RVPH's 103.19%. Michael Burry sees a potential red flag for stagnation or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.18%
Less than half of RVPH's 48.22%. David Dodd sees fewer expansions in other current obligations.
5.07%
Less than half of RVPH's -16.72%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.44%
Less than half of RVPH's 14.29%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
0.54%
Less than half of RVPH's -16.59%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.80%
Below half RVPH's -3.96%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.26%
Below half RVPH's 108.14%. Michael Burry sees potential underperformance in building shareholder capital.
-6.35%
Below half RVPH's 103.19%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.07%
Less than half of RVPH's 451.99%. David Dodd sees less overall debt expansion vs. competitor.
7.30%
Less than half of RVPH's -137.74%. David Dodd sees better deleveraging or stronger cash buildup than competitor.